JP7288913B2 - 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質 - Google Patents

二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質 Download PDF

Info

Publication number
JP7288913B2
JP7288913B2 JP2020548991A JP2020548991A JP7288913B2 JP 7288913 B2 JP7288913 B2 JP 7288913B2 JP 2020548991 A JP2020548991 A JP 2020548991A JP 2020548991 A JP2020548991 A JP 2020548991A JP 7288913 B2 JP7288913 B2 JP 7288913B2
Authority
JP
Japan
Prior art keywords
egfr
antigen binding
scfv
cd16a
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020548991A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019175368A5 (https=
JP2021515798A5 (https=
JP2021515798A (ja
Inventor
クルーゲ、ミカエル
テサール、ミカエル
フセック、イビカ
エルバンガー、クリスティーナ
ロイシュク、ウベ
ダムラット、ミカエル
ラジコビック、エーリヒ
トレダー、マルティン
Original Assignee
アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク filed Critical アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク
Publication of JP2021515798A publication Critical patent/JP2021515798A/ja
Publication of JPWO2019175368A5 publication Critical patent/JPWO2019175368A5/ja
Publication of JP2021515798A5 publication Critical patent/JP2021515798A5/ja
Application granted granted Critical
Publication of JP7288913B2 publication Critical patent/JP7288913B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020548991A 2018-03-14 2019-03-14 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質 Active JP7288913B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18161871 2018-03-14
EP18161871.1 2018-03-14
PCT/EP2019/056516 WO2019175368A1 (en) 2018-03-14 2019-03-14 Bispecific egfr/cd16 antigen-binding protein

Publications (4)

Publication Number Publication Date
JP2021515798A JP2021515798A (ja) 2021-06-24
JPWO2019175368A5 JPWO2019175368A5 (https=) 2022-03-15
JP2021515798A5 JP2021515798A5 (https=) 2022-03-15
JP7288913B2 true JP7288913B2 (ja) 2023-06-08

Family

ID=61683598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020548991A Active JP7288913B2 (ja) 2018-03-14 2019-03-14 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質

Country Status (13)

Country Link
US (2) US11510972B2 (https=)
EP (1) EP3765157A1 (https=)
JP (1) JP7288913B2 (https=)
KR (1) KR102924742B1 (https=)
CN (1) CN111971090B (https=)
AU (1) AU2019235433B2 (https=)
BR (1) BR112020018492A2 (https=)
CA (1) CA3090464A1 (https=)
IL (1) IL276903B2 (https=)
MX (1) MX2020009445A (https=)
SG (1) SG11202007664WA (https=)
WO (1) WO2019175368A1 (https=)
ZA (1) ZA202006247B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276903B2 (en) * 2018-03-14 2025-12-01 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
KR20220119467A (ko) 2019-12-27 2022-08-29 아피메트 게엠베하 이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN116143942A (zh) * 2021-09-09 2023-05-23 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
JP2024543828A (ja) * 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性ｃｄ１６ａバインダー
AU2022382368A1 (en) * 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders
WO2024186092A1 (ko) * 2023-03-06 2024-09-12 주식회사 드노보 바이오테라퓨틱스 신규한 항-cd16 항체 및 이의 용도
WO2024213097A1 (zh) * 2023-04-14 2024-10-17 山东先声生物制药有限公司 一种靶向人cd16和肿瘤抗原的多特异性抗体
WO2025167357A1 (zh) * 2024-02-06 2025-08-14 启愈生物技术(上海)有限公司 Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用
CN118221818B (zh) * 2024-04-29 2025-01-24 四川大学 一种抗cd16a的纳米抗体及其应用
WO2026017120A1 (zh) * 2024-07-18 2026-01-22 信达生物制药(苏州)有限公司 抗cdh17/egfr/cd16a三特异性抗体及其用途
CN118994409B (zh) * 2024-07-30 2025-07-22 郑州市乘黄生物医药科技有限公司 结合CD16A和Trop2的双特异性抗体-NK细胞偶联物及其用途
CN118791616A (zh) * 2024-09-14 2024-10-18 苏州为度生物技术有限公司天津分公司 一种抗人cd16工程抗体及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531470A (ja) 2010-04-20 2013-08-08 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
JP2015502373A (ja) 2011-12-19 2015-01-22 シンイミューン ゲーエムベーハー 二重特異性抗体分子
JP2015524387A (ja) 2012-07-06 2015-08-24 ゲンマブ ビー．ブイ． 三重変異を有する二量体タンパク質
JP2016514676A (ja) 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
WO2016177846A1 (en) 2015-05-04 2016-11-10 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US8289183B1 (en) 2008-04-25 2012-10-16 Texas Instruments Incorporated System and method for solar panel array analysis
CN105153307A (zh) * 2010-05-04 2015-12-16 梅里麦克制药股份有限公司 抗表皮生长因子受体(egfr)的抗体及其用途
CN105555804B (zh) * 2013-08-07 2020-12-25 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
TWI731535B (zh) * 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体
IL276903B2 (en) * 2018-03-14 2025-12-01 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531470A (ja) 2010-04-20 2013-08-08 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
JP2015502373A (ja) 2011-12-19 2015-01-22 シンイミューン ゲーエムベーハー 二重特異性抗体分子
JP2015524387A (ja) 2012-07-06 2015-08-24 ゲンマブ ビー．ブイ． 三重変異を有する二量体タンパク質
JP2016514676A (ja) 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
WO2016177846A1 (en) 2015-05-04 2016-11-10 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Michael Kluge, et al.，High affinity bispecific EGFR/CD16A antibodies specifically recruit NK-cells to target EGFR-expressing tumors，affimed [online]，article no.574，2016年06月23日，[検索日2022-12-26], インターネット <URL: https://www.affimed.com/wp-content/uploads/eacr-aacr-sic_2017_afm24-1.pdf>
浅野竜太郎、熊谷泉，二重特異性抗体のタンパク質工学を駆使した高機能化，薬学雑誌 [online]，135(7)，2015年，p.851-856，［検索日 2022-12-26］, インターネット <URL: https://www.jstage.jst.go.jp/article/yakushi/135/7/135_15-00007-2/_pdf/-char/ja>

Also Published As

Publication number Publication date
BR112020018492A2 (pt) 2020-12-29
KR20200132919A (ko) 2020-11-25
IL276903A (en) 2020-10-29
CN111971090A (zh) 2020-11-20
KR102924742B1 (ko) 2026-02-10
IL276903B2 (en) 2025-12-01
ZA202006247B (en) 2021-09-29
MX2020009445A (es) 2020-10-08
US20230190900A1 (en) 2023-06-22
CN111971090B (zh) 2024-02-23
AU2019235433A1 (en) 2020-08-27
WO2019175368A1 (en) 2019-09-19
US11510972B2 (en) 2022-11-29
CA3090464A1 (en) 2019-09-19
US12076384B2 (en) 2024-09-03
US20200405833A1 (en) 2020-12-31
RU2020131234A (ru) 2022-03-22
AU2019235433B2 (en) 2025-11-20
IL276903B1 (en) 2025-08-01
JP2021515798A (ja) 2021-06-24
EP3765157A1 (en) 2021-01-20
SG11202007664WA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
JP7288913B2 (ja) 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質
CN109641049B (zh) Cd3结合抗体
EP3353212B1 (en) Optimized anti-cd3 bispecific antibodies and uses thereof
TWI706960B (zh) 能夠結合cd19和cd3的雙特異性雙抗體及其用途
CN110041429B (zh) 抗cd-3抗体，与cd3及cd20结合的双特异性抗原结合分子，及其用途
US20250051413A1 (en) Chimeric molecules comprising il-12 agonist polypeptide
JP2021508479A (ja) ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン
TW202128757A (zh) 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CN112399973B (zh) 二聚体及其用途
CN107001485A (zh) 蛋白质异二聚体及其用途
CN106459214A (zh) 用于肿瘤治疗之方法及抗体组成物
KR20210074279A (ko) 항-her2 폴리펩타이드 및 이의 사용방법
EP4467571A1 (en) Anti-cd3 and anti-cd20 bispecific antibody and use thereof
TW202233684A (zh) 結合於葉酸受體α之重鏈抗體
CN111465618A (zh) 双特异性cd16-结合分子及其在疾病治疗中的用途
CN116199778B (zh) 抗4-1bb抗体及其用途
RU2792240C2 (ru) Биспецифический антигенсвязывающий белок egfr/cd16
WO2026046399A1 (en) Anti-dll3 antibodies and use thereof
TW202506729A (zh) Ｓｔｅａｐ２定向ｔ細胞接合物及其組成物
CN117510641A (zh) 靶向cd112r和tigit的双特异性抗体及其用途
JP2022525261A (ja) ビスタ結合抗体およびその使用
WO2022037582A1 (zh) 抗cd3和抗cldn-18.2双特异性抗体及其用途
HK1258304B (en) Optimized anti-cd3 bispecific antibodies and uses thereof
CA2967820A1 (en) Methods for tumor treatment using cd3xcd20 bispecific antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230529

R150 Certificate of patent or registration of utility model

Ref document number: 7288913

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150